Acrolein consumption induces systemic dyslipidemia and lipoprotein modification

Toxicology and Applied Pharmacology

Volumn 243, Issue 1, 2010, Pages 1-12

  Conklin, Daniel J ^a   Barski, Oleg A ^a   Lesgards, Jean Francois ^a   Juvan, Peter ^b   Rezen, Tadeja ^b   Rozman, Damjana ^b   Prough, Russell A ^a   Vladykovskaya, Elena ^a   Liu, SiQi ^a   Srivastava, Sanjay ^a   Bhatnagar, Aruni ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Acute phase response; Aldehyde; Cholesterol; Hepatic lipase; Lipoproteins; Triglycerides

Indexed keywords

ACROLEIN; APOLIPOPROTEIN E; CHOLESTEROL; CREATININE; CYTOKINE; ELECTROLYTE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LIVER ENZYME; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; NITROGEN; PHOSPHOLIPID; TRIACYLGLYCEROL; UREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT ANIMAL; AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHROMATOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; ENZYME ACTIVITY; EXPOSURE; FEEDING; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ACROLEIN; ANIMALS; APOLIPOPROTEINS E; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; LIPASE; LIPOPROTEINS; LIVER; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

MUS;

EID: 75149190856     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.010     Document Type: Article

References (55)

1. Ahima R.S., Prabakaran D., Mantzoros C., Qu D., Lowell B., Maratos-Flier E., and Flier J.S. Role of leptin in the neuroendocrine response to fasting. Nature 382 (1996) 250-252
2. Alarcon R.A. Acrolein: IV. Evidence for the formation of the cytotoxic aldehyde acrolein from enzymatically oxidized spermine or spermidine. Arch. Biochem. Biophys. 137 (1970) 365-372
3. Anderson M.M., Hazen S.L., Hsu F.F., and Heinecke J.W. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest 99 (1997) 424-432
4. Appelman L.M., Hendriksen C.F., and Feron V.J. Repeated exposure to alpha-ethylacrolein vapour: subacute toxicity study in rats. Toxicology 22 (1981) 79-87
5. Arikketh D., Niranjali S., and Devaraj H. Detection of acrolein-lysine adducts in plasma low-density lipoprotein and in aorta of cyclophosphamide-administered rats. Arch. Toxicol. 78 (2004) 397-401
6. Beauchamp Jr. R.O., Andjelkovich D.A., Kligerman A.D., Morgan K.T., and Heck H.D. A critical review of the literature on acrolein toxicity. Crit. Rev. Toxicol. 14 (1985) 309-380
7. Bhatnagar A. Cardiovascular pathophysiology of environmental pollutants. Am. J. Physiol. Heart Circ. Physiol. 286 2 (2004) H479-H485
8. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 8 (1959) 911-917
9. Boor P.J. Allylamine cardiotoxicity: metabolism and mechanism. Adv. Exp. Med. Biol. 161 (1983) 533-541
10. Boren J., Lookene A., Makoveichuk E., Xiang S., Gustafsson M., Liu H., Talmud P., and Olivecrona G. Binding of low density lipoproteins to lipoprotein lipase is dependent on lipids but not on apolipoprotein B. J. Biol. Chem. 276 (2001) 26916-26922
11. Brock N., Stekar J., Pohl J., Niemeyer U., and Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 29 (1979) 659-661
12. Chen Y., Joaquim L.F., Farah V.M., Wichi R.B., Fazan Jr. R., Salgado H.C., and Morris M. Cardiovascular autonomic control in mice lacking angiotensin AT1a receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R1071-R1077
13. Committee on Aldehydes. Formaldehyde and Other Aldehydes (1981), National Academy Press, Washington D.C
14. Cox P.J. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem. Pharmacol. 28 (1979) 2045-2049
15. Dousset N., Loudet A.M., Lespine A., Carton M., Douste-Blazy L., and Chap H. Apolipoproteins induced by an antimitotic agent. Adv. Exp. Med. Biol. 210 (1987) 201-208
16. Egle Jr. J.L., and Hudgins P.M. Dose-dependent sympathomimetic and cardioinhibitory effects of acrolein and formaldehyde in the anesthetized rat. Toxicol. Appl. Pharmacol. 28 3 (1974) 358-366
17. Espenshade P.J., and Hughes A.L. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41 (2007) 401-427
18. Fan J., Molina P.E., Gelato M.C., and Lang C.H. Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 134 (1994) 1685-1692
19. Feng Z., Hu W., Hu Y., and Tang M.S. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc. Natl. Acad. Sci. U. S. A 103 (2006) 15404-15409
20. Feron V.J., Til H.P., de Vrijer F., Woutersen R.A., Cassee F.R., and van Bladeren P.J. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat. Res. 259 (1991) 363-385
21. Fullana A., Carbonell-Barrachina A.A., and Sidhu S. Comparison of volatile aldehydes present in the cooking fumes of extra virgin olive, olive, and canola oils. J. Agric. Food Chem. 52 (2004) 5207-5214
22. Ghilarducci D.P., and Tjeerdema R.S. Fate and effects of acrolein. Rev. Environ. Contam. Toxicol. 144 (1995) 95-146
23. Gonzalez-Navarro H., Nong Z., Amar M.J., Shamburek R.D., Najib-Fruchart J., Paigen B.J., Brewer Jr. H.B., and Santamarina-Fojo S. The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J. Biol. Chem. 279 (2004) 45312-45321
24. Green M.A., and Egle Jr. J.L. Effects of intravenous acetaldehyde, acrolein, formaldehyde and propionaldehyde on arterial blood pressure following acute guanethidine treatment. Res. Commun. Chem. Pathol. Pharmacol. 40 (1983) 337-340
25. Hammad S.M., Powell-Braxton L., Otvos J.D., Eldridge L., Won W., and Lyons T.J. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 52 (2003) 916-921
26. Henderson R.F. Species differences in the metabolism of olefins: implications for risk assessment. Chem.-Biol. Interact. 135-136 (2001) 53-64
27. Hevonoja T., Pentikainen M.O., Hyvonen M.T., Kovanen P.T., and la-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta 1488 (2000) 189-210
28. Homanics G.E., de Silva H.V., Osada J., Zhang S.H., Wong H., Borensztajn J., and Maeda N. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J. Biol. Chem. 270 (1995) 2974-2980
29. Ilanchezhian S., Thangaraju M., Sasirekha S., and Sachdanandam P. Alpha-tocopherol ameliorates cyclophosphamide-induced hyperlipidemia in fibrosarcoma-bearing rats. Anticancer Drugs 6 (1995) 771-774
30. Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., and Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45 (2004) 1169-1196
31. Kitagawa S., Yamaguchi Y., Imaizumi N., Kunitomo M., and Fujiwara M. A uniform alteration in serum lipid metabolism occurring during inflammation in mice. Jpn. J. Pharmacol. 58 (1992) 37-46
32. Knouff C., Hinsdale M.E., Mezdour H., Altenburg M.K., Watanabe M., Quarfordt S.H., Sullivan P.M., and Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest 103 (1999) 1579-1586
33. Koch A., Konig B., Spielmann J., Leitner A., Stangl G.I., and Eder K. Thermally oxidized oil increases the expression of insulin-induced genes and inhibits activation of sterol regulatory element-binding protein-2 in rat liver. J. Nutr. 137 (2007) 2018-2023
34. Lambert C., McCue J., Portas M., Ouyang Y., Li J., Rosano T.G., Lazis A., and Freed B.M. Acrolein in cigarette smoke inhibits T-cell responses. J. Allergy Clin. Immunol. 116 (2005) 916-922
35. Lambert C., Li J., Jonscher K., Yang T.C., Reigan P., Quintana M., Harvey J., and Freed B.M. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J. Biol. Chem. 282 (2007) 19666-19675
36. Li L., Hamilton Jr. R.F., Taylor D.E., and Holian A. Acrolein-induced cell death in human alveolar macrophages. Toxicol. Appl. Pharmacol. 145 (1997) 331-339
37. Li H., Wang J., Kaphalia B., Ansari G.A., and Khan M.F. Quantitation of acrolein-protein adducts: potential biomarker of acrolein exposure. J. Toxicol. Environ. Health A. 67 (2004) 513-524
38. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
39. Loudet A.M., Dousset N., Carton M., and Douste-Blazy L. Effect of an antimitotic agent (cyclophosphamide) on post-heparin plasma lipoprotein lipase activity in rabbit. Biochem. Pharmacol. 34 (1985) 3597-3599
40. Loudet A.M., Dousset N., Perret B., Ierides M., Carton M., and Douste-Blazy L. Triacylglycerol increase in plasma very low density lipoproteins in cyclophosphamide-treated rabbit: relationship with cholesteryl ester transfer activity. Biochim. Biophys. Acta 836 (1985) 376-384
41. Lovell M.A., Xie C., and Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 22 (2001) 187-194
42. Luo J., Hill B.G., Gu Y., Cai J., Srivastava S., Bhatnagar A., and Prabhu S.D. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3673-H3684
43. Nakamura H., Kouda K., Tokunaga R., and Takeuchi H. Suppressive effects on delayed type hypersensitivity by fasting and dietary restriction in ICR mice. Toxicol. Lett. 146 (2004) 259-267
44. Nawrocki J., Dabrowska A., and Borcz A. Investigation of carbonyl compounds in bottled waters from Poland. Water Res. 36 (2002) 4893-4901
45. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am. J. Cardiol. 90 (2002) 22i-29i
46. Parent R.A., Caravello H.E., Balmer M.F., Shellenberger T.E., and Long J.E. One-year toxicity of orally administered acrolein to the beagle dog. J. Appl. Toxicol. 12 (1992) 311-316
47. Parent R.A., Caravello H.E., and Sharp D.E. Metabolism and distribution of [2,3-14C]acrolein in Sprague-Dawley rats. J. Appl. Toxicol. 16 (1996) 449-457
48. Sakata K., Kashiwagi K., Sharmin S., Ueda S., and Igarashi K. Acrolein produced from polyamines as one of the uraemic toxins. Biochem. Soc. Trans. 31 (2003) 371-374
49. Santamarina-Fojo S., Gonzalez-Navarro H., Freeman L., Wagner E., and Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1750-1754
50. Srivastava S., Chandrasekar B., Bhatnagar A., and Prabhu S.D. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am. J. Physiol. Heart Circ. Physiol 283 (2002) H2612-H2619
51. Tous M., Ribas V., Ferre N., Escola-Gil J.C., Blanco-Vaca F., onso-Villaverde C., Coll B., Camps J., and Joven J. Turpentine-induced inflammation reduces the hepatic expression of the multiple drug resistance gene, the plasma cholesterol concentration and the development of atherosclerosis in apolipoprotein E deficient mice. Biochim. Biophys. Acta 1733 (2005) 192-198
52. Tsakadze N.L., Srivastava S., Awe S.O., Adeagbo A.S., Bhatnagar A., and D'Souza S.E. Acrolein-induced vasomotor responses of rat aorta. Am. J. Physiol Heart Circ. Physiol. 285 (2003) H727-H734
53. Vesely P., Lusk L., Basarova G., Seabrooks J., and Ryder D. Analysis of aldehydes in beer using solid-phase microextraction with on-fiber derivatization and gas chromatography/mass spectrometry. J. Agric. Food Chem. 51 (2003) 6941-6944
54. Wang G.W., Guo Y., Vondriska T.M., Zhang J., Zhang S., Tsai L.L., Zong N.C., Bolli R., Bhatnagar A., and Prabhu S.D. Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. J. Mol. Cell. Cardiol. 44 (2008) 1016-1022
55. Zemski Berry K.A., and Murphy R.C. Characterization of acrolein-glycerophosphoethanolamine lipid adducts using electrospray mass spectrometry. Chem. Res. Toxicol. 20 (2007) 1342-1351